TJ BioTech LLC has announced that, as of June 11, 2026, ReMedium TI has received a full Section 3 label and registration from the U.S. Environmental Protection Agency, along with state approval from the Florida Department of Agriculture and Consumer Services.
The approved label allows for two consecutive years of treatment, starting with the 2026–27 season, followed by a one-year break in treatment. Always read and follow label instructions when using ReMedium TI.
“This label approval represents a highly significant milestone for the Florida citrus industry,” says TJ BioTech President Tom Johnson. “Our company continues to lead the development of commercially viable solutions to combat HLB (citrus greening) disease. ReMedium TI has demonstrated proven performance in improving tree health, resulting in greater yield and fruit quality. This innovative injection therapy delivers substantial economic benefits to citrus growers.”
Many Florida citrus growers have made their third treatment to trees, with most cases showing continuing improvement in yield and quality as the cumulative benefits of oxytetracycline (OTC) grow over time. The new label was welcome news to growers and the citrus industry, as it will allow for continued momentum in the coming seasons.
During the recent Florida Citrus Industry Annual Conference, Ute Albrecht, University of Florida Institute of Food and Agricultural Sciences associate professor, gave an update on her ongoing research on the use of OTC to reduce HLB titer. Albrecht’s work has shown that OTC has cumulative benefits over time in improving yield, especially after three years of treatment. She also noted that the quality of juice is improving in year three of OTC applications.
“The juice this season was fantastic tasting,” Albrecht said. “It reminds you of the juice quality and taste before HLB.”
Share this Post